Page last updated: 2024-12-08

5-methoxy-n,n-diisopropyltryptamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-methoxy-N,N-diisopropyltryptamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151182
CHEMBL ID2140942
CHEBI ID48282
SCHEMBL ID896818
MeSH IDM0104429

Synonyms (34)

Synonym
PDSP1_000761
PDSP2_000749
5-meo-dipt
n-(1-methylethyl)-n-{2-[5-(methyloxy)-1h-indol-3-yl]ethyl}propan-2-amine
5-methoxy-n,n-bis(1-methylethyl)-1h-indole-3-ethanamine
5-methoxy-n,n-diisopropyltryptamine
foxy methoxy
DB01441
foxy
n-{2-[5-(methyloxy)-1h-indol-3-yl]ethyl}-n-(propan-2-yl)propan-2-amine
4021-34-5
CHEBI:48282 ,
n-isopropyl-n-[2-(5-methoxy-1h-indol-3-yl)ethyl]propan-2-amine
n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-n-propan-2-ylpropan-2-amine
dea no. 7439
unii-12d06g8w8e
12d06g8w8e ,
1h-indole-3-ethanamine, 5-methoxy-n,n-bis(1-methylethyl)-
methoxy foxy
FT-0630092
AKOS015894311
AM20120626
3-(2-(diisopropylamino)ethyl)-5-methoxyindole
5-methoxy-n,n-diisopropyltryptamine [mi]
SCHEMBL896818
n-isopropyl-n-(2-(5-methoxy-1h-indol-3-yl)ethyl)propan-2-amine
CHEMBL2140942
DNBPMBJFRRVTSJ-UHFFFAOYSA-N
DTXSID00193209
BCP15442
Q2983762
5-methoxy-n,n-diisopropyltryptamine(5-meo-dipt)
4,4-di-n-hexyloxybiphenyl
PD008862

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It produces serious adverse effects, but its pharmacological profile is not well recognized."( Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.
Gołembiowska, K; Kamińska, K; Kreiner, G; Noworyta-Sokołowska, K; Rogóż, Z, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
hallucinogenDrugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tryptaminesTryptamine and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's0 (0.00)18.2507
2000's21 (65.63)29.6817
2010's7 (21.88)24.3611
2020's3 (9.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.63 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies9 (26.47%)4.05%
Observational0 (0.00%)0.25%
Other23 (67.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]